Title: A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
Journal: The New England journal of medicine20130725
Title: Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.
Journal: Proceedings of the National Academy of Sciences of the United States of America20121226
Title: The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Journal: Drug metabolism and disposition: the biological fate of chemicals20121001
Title: Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
Journal: Journal of clinical pharmacology20120601
Title: miR-9 controls the timing of neurogenesis through the direct inhibition of antagonistic factors.
Journal: Developmental cell20120515
Title: A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.
Journal: Journal of neuropathology and experimental neurology20120501
Title: First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
Journal: The Journal of biological chemistry20120406
Title: Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Journal: Journal of neurochemistry20120401
Title: QT effect of semagacestat at therapeutic and supratherapeutic doses.
Journal: International journal of clinical pharmacology and therapeutics20120401
Title: Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience20120208
Title: A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.
Journal: Journal of Alzheimer's disease : JAD20120101
Title: Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.
Journal: Neuro-degenerative diseases20120101
Title: Translatability scoring in drug development: eight case studies.
Journal: Journal of translational medicine20120101
Title: Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
Journal: Expert opinion on drug discovery20120101
Title: Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.
Journal: PloS one20120101
Title: Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.
Journal: Journal of Alzheimer's disease : JAD20120101
Title: γ-Secretase modulator in Alzheimer's disease: shifting the end.
Journal: Journal of Alzheimer's disease : JAD20120101
Title: pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.
Journal: Journal of biological regulators and homeostatic agents20120101
Title: Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Journal: The Journal of pharmacology and experimental therapeutics20111201
Title: [Gamma-secretase inhibitors and modulators].
Journal: Nihon rinsho. Japanese journal of clinical medicine20111201
Title: Drugs: a tangled web of targets.
Journal: Nature20110713
Title: Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association20110701
Title: What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Journal: Annals of neurology20110201
Title: New pathway links γ-secretase to inflammation and memory while sparing notch.
Journal: Annals of neurology20110101
Title: Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.
Journal: Journal of Alzheimer's disease : JAD20110101
Title: BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.
Journal: Journal of biomedical science20110101
Title: Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Journal: Current medicinal chemistry20110101
Title: Genetics. Gamma-secretase and human disease.
Journal: Science (New York, N.Y.)20101119
Title: What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
Journal: Biological psychiatry20101115
Title: Alzheimer's failure raises questions about disease-modifying strategies.
Journal: Nature reviews. Drug discovery20101001
Title: NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
Journal: Annals of neurology20101001
Title: ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
Journal: ACS chemical neuroscience20100818
Title: [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica20100701
Title: Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals20100401
Title: In response to 'a gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system'.
Journal: Annals of neurology20100101
Title: Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Journal: Journal of Alzheimer's disease : JAD20100101
Title: Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.
Journal: Alzheimer's research & therapy20100101
Title: Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.
Journal: Alzheimer's research & therapy20100101
Title: Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Journal: Journal of medicinal chemistry20091022
Title: Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Journal: Journal of neurochemistry20090901
Title: A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
Journal: Annals of neurology20090701
Title: Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Journal: Expert opinion on pharmacotherapy20090701
Title: Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Journal: Current opinion in investigational drugs (London, England : 2000)20090701
Title: gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice.
Journal: Biochemical and biophysical research communications20090529
Title: Committed neuronal precursors confer astrocytic potential on residual neural precursor cells.
Journal: Developmental cell20090201
Title: Requirement of Notch activation during regeneration of the intestinal epithelia.
Journal: American journal of physiology. Gastrointestinal and liver physiology20090101
Title: A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.
Journal: PloS one20090101
Title: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.
Journal: Molecular neurodegeneration20090101
Title: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Journal: The Journal of pharmacology and experimental therapeutics20081101
Title: Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.
Journal: Blood20080901
Title: Molecule of the month. Semagacestat.
Journal: Drug news & perspectives20080901
Title: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Journal: Archives of neurology20080801
Title: A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.
Journal: Bioorganic & medicinal chemistry letters20071115
Title: Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase.
Journal: The Journal of biological chemistry20071102
Title: Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
Journal: Bioorganic & medicinal chemistry letters20071101
Title: Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.
Journal: The Journal of biological chemistry20070824
Title: Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.
Journal: The Journal of pharmacology and experimental therapeutics20070301
Title: Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Journal: Clinical neuropharmacology20070101
Title: Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Journal: The Journal of pharmacology and experimental therapeutics20061201
Title: Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
Journal: The Journal of pharmacology and experimental therapeutics20061101
Title: [The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20060701
Title: Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Journal: Neurology20060227
Title: Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Journal: The Journal of pharmacology and experimental therapeutics20050501
Title: Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.
Journal: Clinical neuropharmacology20050101
Title: Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
Journal: The Journal of pharmacology and experimental therapeutics20040401
Title: Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82.
Title: Otoguro T, et al. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol. 2016 Nov;60(11):740-753
Title: Curry CL, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005 Sep 22;24(42):6333-44.
Title: Zhang J, et al. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochem Cell Biol. 2017 Mar;147(3):367-375.
Title: Hyde LA, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,dazepin-7-yl-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43.
